ACTION VAD注册研究:五年协作经验
ACTION VAD注册研究汇总2018年4月至2023年6月北美57个中心、1220例≤18岁患儿的1430例VAD植入数据,描述患者与装置特征及植入后1年结局。1年总生存率79.2%,卒中发生率13.7%,婴儿结局最差。
要点
- 婴儿VAD植入后1年生存率72.9%,卒中发生率20.8%,结局最差。
- 先天性心脏病患者占VAD植入比例从2018年26%升至2023年42%。
- 植入时25%患者使用ECMO,54%机械通气,4.9%透析。
核心结论
- 五年ACTION VAD经验显示儿科VAD领域协作增强且临床实践发生变化,需改进生存并减少不良结局,尤其年幼患者。
研究设计与样本
- 基于ACTION学习网络2018年4月至2023年6月提交数据的注册报告,纳入北美57个中心1220例≤18岁患儿的1430例VAD植入。
主要发现
- 男性占55%,中位年龄3.7岁,中位植入体重13.6 kg,36%体重<10 kg。
- 近40%患者主要诊断为先天性心脏病,其占VAD植入比例从2018年26%增至2023年42%(p=0.03)。
- 植入时25%使用ECMO,4.9%透析,54%机械通气。
- 体外搏动泵占40.2%,体外连续流占28.5%,植入式连续流占24.1%。
- 1年总生存率79.2%,卒中发生率13.7%;婴儿1年生存率72.9%,卒中发生率20.8%。
临床怎么用
- 儿科VAD患者中先天性心脏病占比上升,植入时较多患者依赖ECMO和机械通气,婴儿不良事件风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Advanced Cardiac Therapies Improving Outcomes Network (ACTION) began in 2018 as a collaborative learning health system committed to improving outcomes in pediatric heart failure, including children and adults with congenital heart disease, supported with ventricular assist devices (VADs). This report describes patient and device characteristics, and outcomes through 1-year post-implant. METHODS: The ACTION VAD registry report was created from data submitted to the ACTION learning network from April 2018 to June 2023. It includes 1,430 devices implanted in 1,220 pediatric patients (≤18) from 57 sites across North America. RESULTS: Males comprised 55% of the registry patients. The median age was 3.7 years with a median implant weight of 13.6 kg; 36% of the cohort was <10 kg. Nearly 40% of patients had a primary diagnosis of congenital heart disease (CHD). Patients with CHD represented 26% of VAD implants in 2018 which increased to 42% in 2023 (p=0.03). At implant, 25% of patients were supported with extracorporeal membrane oxygenation (ECMO), 4.9% with dialysis, and 54% were mechanically ventilated. Paracorporeal pulsatile pumps comprised 40.2% of implants, followed in incidence by paracorporeal continuous flow (28.5%), and implantable continuous flow (24.1%). The number of patients in the VAD Registry patients increased from 102 in 2018 to 256 in 2022, partly reflecting increased center participation in ACTION. Overall survival on support at 1 year was 79.2%, and the incidence of stroke was 13.7%. Infants demonstrated the poorest outcomes, with a 1-year survival of 72.9% and a higher incidence of stroke (20.8%). CONCLUSION: The 5-year ACTION VAD experience highlights the growing collaboration in the pediatric VAD community and changes in clinical practice. More work is needed to improve survival and limit adverse outcomes, especially in younger patients.
引用
- Edelson JB, Raskin A, Absi M, et al. The ACTION VAD registry: A collective five-year experience. J Heart Lung Transplant. 2025. PMID: 39827929. doi:10.1016/j.healun.2025.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。